Price Chart

Profile

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
URL https://www.novonordisk.com
Investor Relations URL https://www.novonordisk.com/investors.html
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release May. 02, 2024
Last Earnings Release Nov. 02, 2023
Next Ex-Dividend Date Mar. 22, 2024
Last Ex-Dividend Date Aug. 18, 2023

Profile

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
URL https://www.novonordisk.com
Investor Relations URL https://www.novonordisk.com/investors.html
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release May. 02, 2024
Last Earnings Release Nov. 02, 2023
Next Ex-Dividend Date Mar. 22, 2024
Last Ex-Dividend Date Aug. 18, 2023